Open an account

Praxis Precision Medicines

PRAX · NASDAQ

$264.49+$4.32 (+1.66%)TodayMarket closed ·
Prev close $260.17

About PRAX

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 168 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

Employees
168
Headquarters
Boston, Massachusetts
Listed
Oct 16, 2020
Sector
Health Care
Industry
Biotechnology
Website
praxismedicines.com

PRAX key statistics

Market cap
7.38B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
575.79K
Volume
886.07K
Open price
$259.40
High today
$270.33
Low today
$258.03
52 Week high
$392.70
52 Week low
$154.45

Praxis Precision Medicines (PRAX) at a glance

Praxis Precision Medicines (PRAX) last traded at $264.49, with a market cap of 7.38B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $258.03 and $270.33. The current price is 2.5% above the day's low and 2.2% below its high.

Volume so far is 886.07K shares, above the average of 575.79K shares a day.

Over the past year Praxis Precision Medicines has ranged from $154.45 to $392.70, and now sits 46% of the way up that range.

Praxis Precision Medicines met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$2.87 per share against an estimate of -$3.73.

The average analyst price target is $641.79, 142.7% above the current price, from 19 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

89%of 19 analyst ratings say Buy
  • Buy89.5%
  • Hold5.3%
  • Sell5.3%
Price target · 21 analystsAvg $641.79
Low
$189.88
Now
$264.49
High
$1,261.05

PRAX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 10.2% on average.

  1. Q3 FY24: reported -$2.75 per share against an estimate of -$2.03
  2. Q4 FY24: reported -$2.94 per share against an estimate of -$2.90
  3. Q1 FY25: reported -$3.29 per share against an estimate of -$3.27
  4. Q2 FY25: reported -$3.31 per share against an estimate of -$3.40
  5. Q3 FY25: reported -$3.36 per share against an estimate of -$3.51
  6. Q4 FY25: reported -$3.50 per share against an estimate of -$3.16
  7. Q1 FY26: reported -$3.20 per share against an estimate of -$3.58
  8. Q2 FY26: reported -$2.87 per share against an estimate of -$3.73

PRAX news

  • Praxis Precision Medicine Q2 2026 Earnings Call Transcript

  • Press releaseGlobe Newswire

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

  • Vandana Singh

    Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results

  • Vandana Singh

    Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

  • Press releaseGlobe Newswire

    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

  • Vandana Singh

    Why Is Praxis Precision Stock Soaring Tuesday?

  • Press releaseGlobe Newswire

    Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

  • Earnings Outlook For Praxis Precision Medicine

Similar companies

Companies in the same industry as Praxis Precision Medicines

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.